Document is current
Any future updates will be listed below
-
Authors
Tokarew, Jacqueline M.
El-Kodsi, Daniel N.
Lengacher, Nathalie A.
Fehr, Travis K.
Nguyen, Angela P.
Shutinoski, Bojan
O’Nuallain, Brian
Jin, Ming
Khan, Jasmine M.
Ng, Andy C. H.
Li, Juan
Jiang, Qiubo
Zhang, Mei
Wang, Liqun
Sengupta, Rajib
Barber, Kathryn R.
Tran, An
Im, Doo Soon
Callaghan, Steve
Park, David S.
Zandee, Stephanie
Dong, Xiajun
Scherzer, Clemens R.
Prat, Alexandre
Tsai, Eve C.
Takanashi, Masashi
Hattori, Nobutaka
Chan, Jennifer A.
Zecca, Luigi
West, Andrew B.
Holmgren, Arne
Puente, Lawrence
Shaw, Gary S.
Toth, Gergely
Woulfe, John M.
Taylor, Peggy
Tomlinson, Julianna J.
Schlossmacher, Michael G. https://orcid.org/0000-0002-0394-0300
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research
- License Information
-
More Information
Article History
Received: 20 November 2020
Revised: 11 January 2021
Accepted: 13 January 2021
First Online: 10 March 2021
Compliance with ethical standards
:
: Drs. B. O’Nuallain, M. Jin, L. Wang, P. Taylor are (or were) employees of BioLegend Inc. (Dedham, MA., USA). The Ottawa Hospital receives payments from BioLegend Inc. related to licensing agreements for immunological reagents related to parkin and α-synuclein. Dr. M. Schlossmacher received travel reimbursements from the Michael J. Fox Foundation for Parkinson’s Research for participation in industry summits and consulting fees as well as royalties from Genzyme-Sanofi for patents unrelated to this work. Dr. G. Toth is an employee and a shareholder of Cantabio Pharmaceuticals. Dr. A. Holmgren (deceased) served as chairman and senior scientist at IMCO Corporation Ltd AB, Stockholm, Sweden. No additional, potentially competing financial interests are declared.
